RIG-I Like Receptors in Antiviral Immunity and Therapeutic Applications by Ireton, Reneé C. & Gale, Michael
Viruses 2011, 3, 906-919; doi:10.3390/v3060906 
 
viruses
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
RIG-I Like Receptors in Antiviral Immunity and Therapeutic 
Applications 
Reneé C. Ireton and Michael Gale, Jr. * 
Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA; 
E-Mail: rireton@u.washington.edu 
*  Author to whom correspondence should be addressed; E-Mail: mgale@u.washington.edu;  
Tel.: +1-206-543-8514; Fax: +1-206-543-1013. 
Received: 9 April 2011; in revised form: 4 June 2011 / Accepted: 9 June 2011 /  
Published: 23 June 2011 
 
Abstract: The RNA helicase family of RIG-I-like receptors (RLRs) is a key component of 
host  defense  mechanisms responsible for detecting viruses and triggering innate immune 
signaling  cascades  to  control  viral  replication  and  dissemination.  As  cytoplasm-based 
sensors,  RLRs  recognize  foreign  RNA  in  the  cell  and  activate  a  cascade  of  antiviral 
responses  including  the  induction  of  type  I  interferons,  inflammasome  activation,  and 
expression  of  proinflammatory  cytokines  and  chemokines.  This  review  provides  a  brief 
overview of RLR function, ligand interactions, and downstream signaling events with an 
expanded discussion on the therapeutic potential of targeting RLRs for immune stimulation 
and treatment of virus infection. 
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1. Introduction  
Cell-intrinsic  innate immune defenses are our first line of resistance against infections caused by 
harmful  pathogens.  Both  immune  and  non-immune  cells  alike  are  armed  with  the  ability  to  detect 
pathogens and alert the innate immune system of their presence. In recent years, pattern recognition 
receptors  (PRRs),  such  as  Toll-like  receptors  (TLRs),  RIG-I-like  receptors  (RLRs),  and  Nod-like 
receptors (NLRs), have been defined as factors that recognize pathogen-associated molecular patterns 
(PAMPs).  PAMPs  are  non-self  motifs  embedded  in  the  molecular  structure  of  pathogen-specific 
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macromolecules and are recognized as non-self through interaction with certain PRRs. PAMP-PRR 
interactions lead to induction of signaling events that activate innate immunity [1]. The various PRRs 
are  differentially  expressed  within  the  cellular  compartments  and  demonstrate  specific  affinities  for 
various pathogen-intrinsic molecular structures. In particular, the RLR family of PRRs has emerged as a 
key cellular sensor of RNA virus infection. Once activated by binding to an RNA PAMP ligand, the 
RLRs trigger a multitude of downstream signaling cascades that lead to antiviral host responses, such as 
the induction of type-I interferons, inflammasome activation, and the expression of proinflammatory 
cytokines  and chemokines. This review focuses specifically on RLR mechanism of action, potential 
methods of cellular surveillance, and the role of RLR agonists in possible new therapeutic applications.  
2. Structure and Functional Mechanisms of RLRs 
The RLR family of PRRs is comprised of three members: Retinoic acid-inducible gene I (RIG-I), 
melanoma  differentiation-associated  gene  5  (MDA5),  and  laboratory  of  genetics  and  physiology  2 
(LGP2). All members contain a centrally located DExH-box helicase domain, while only RIG-I and 
MDA5, but not LGP2, have two caspase recruitment domains (CARDs) located at the N-terminus. In 
contrast,  both  RIG-I  and  LGP2  contain  a  C-terminal  repressor  domain  that  regulates  signaling  by 
holding the molecule in a closed, signaling-off state until ligand binding leads to its altered conformation 
of a signaling-on state that drives antiviral defenses [2].  
The RLRs reside in the cytoplasm, where they survey cellular contents for the presence of RNA 
viruses [2]. As detailed descriptions of the signaling cascades activated by RLRs have been provided in 
previous reviews [3–5], we provide only a brief description of the RIG-I signaling process below. In the 
presence of RNA ligand binding, an ATP-dependent conformational change occurs and the activated 
CARD  domains  are  released  from  signaling  repression  to  induce  signaling  by  interacting  with  the 
adaptor  molecule,  IPS-1  (also  known  as  MAVS,  VISA,  and  Cardif).  Activation  of  IPS-1,  in  turn 
triggers  signaling  cascades  involving  TRAF3/6,  caspase  8/10,  RIP-1,  Fas-associated  death  domain 
(FADD), and TNF receptor-associated death domain (TRADD). These signaling cascades ultimately 
activate the kinase activity of the TBK1/IKK- and IKKα/IKKβ complexes to induce transcription of 
type-I IFNs and proinflammatory cytokines by activating the NF-κB and IRF-3 transcription factors [4]. 
A large number of recent studies have begun to identify the varied mechanisms by which the RLR 
signaling  pathway  is  modulated  and  have  identified  a  variety of RLR interacting/signaling partners. 
These factors include adaptor and signaling proteins such as TRAF3, TRAF2, TRAF6, TANK, SIKE, 
NEMO/IKK,  FADD,  RIP1,  TRADD,  caspase 8/10, and STING/MITA/MPYS as well as negative 
signaling  regulators  such  as  RNF125,  ISG15,  DAK,  Atg12-Atg5,  NLRX1,  caspase-1,  and  several 
deubiquitinating enzymes (reviewed in detail in [6,7]). Indeed, other studies have shown that RIG-I is 
directly mediated through ubiquitination or the interaction with free ubiquitin [8,9].  
Together  with  the  RLRs,  these  factors  serve  to  direct  downstream  signaling  that  drives  IFN 
expression and secretion from the virus-infected cell. Secreted IFN drives both autocrine and paracrine 
immune signaling in the infected cell and surrounding cells in the local tissue, respectively. Activation of 
the  interferon  receptor  stimulates  the  JAK-STAT  pathway,  which  ultimately  induces  the  nuclear 
localization  of  ISGF3,  the  central  transcription factor responsible for promoting high expression of 
interferon stimulated genes (ISGs).  This second wave of transcriptional activity directed by IFN to Viruses 2011, 3                         
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initiate ISG expression creates a powerful immune response. The hundreds of ISGs encoded by the 
human genome [10] have yet to be thoroughly examined and functionally characterized, but the protein 
products of a subset of these genes are known to be potent immunomodulators and antivirals. Viewed 
in this light, pathways such as the RLRs that lead to the triggering of ISG induction become interesting 
targets for designing therapeutics aimed at inducing the powerful ISG response.  
3. Ligand Recognition by RLRs 
RIG-I and MDA5 are essential and sufficient for the induction of innate immune defenses and type-I 
interferon responses to RNA viruses, as cells lacking both factors failed to produce type-I IFNs when 
exposed to certain RNA viruses [11,12]. However, with the exception of reoviruses, paramyxoviruses, 
and flaviviruses including Dengue virus and West Nile virus; RIG-I and MDA5 each trigger innate 
antiviral response and IFN expression in response to specific sets of viruses. The virus specificity of 
RIG-I and MDA5 is intrinsic to the RNA species they detect: RIG-I detects RNA marked with 5’ 
triphosphates (5’ppp) and containing short dsRNA structure motifs and/or poly-uridine motifs that mark 
an RNA as non-self [13–18]. MDA5 is thought to bind to activated long, stable dsRNA structures such 
as RNA replication intermediates that might be hybridized to genome RNA during infection [11]. RIG-I 
detects both positive and negative strand RNA viruses including Japanese encephalitis virus, Sendai 
virus,  vesicular  stomatitis  virus,  influenza  virus,  Hepatitis  C  virus,  respiratory  syncytial  virus,  and 
Newcastle disease virus; while MDA5  has been shown to specifically detect picornaviruses such as 
encephalomyocarditis virus, Mengo virus, and Theiler’s virus. More recent work has found that RIG-I 
and MDA5 can also detect rotavirus in infected intestinal epithelium [19,20]. Importantly, MDA5 also 
appears to be the primary RLR for detecting poly(I:C), the memetic of dsRNA. RIG-I also recognizes 
cellular RNA polymerase III-derived RNA that can be generated from viral DNA templates, thereby 
linking  RIG-I  signaling  with  DNA  virus  infection  [21].  Table  1  features  the  ligands  known  to  be 
recognized by each RLR family member.  
The ligand recognition properties of LGP2 are less well-defined, and it is not known if LGP2 serves 
as a primary PRR to detect virus infection or if it serves as a signaling or regulatory cofactor of the 
other RLRs. Conflicting data have indicated that LGP2 can serve as either a positive or a negative 
regulator  of  RLR  signaling,  depending  on  the  experimental  platform  or  virus  infection  being  
assessed [22,23]. Future experimental analyses are needed to address the ligand binding activity and 
specificity of LGP2 and its role in triggering RLR signaling cascades.  
Intriguing  recent  work  has  shed  light  on  the  physical  mechanism  by  which  RIG-I  conducts  its 
cytoplasmic patrol for viral-derived RNA invaders. The process of how RIG-I patrols the cytoplasm and 
detects  ligand  can  be  described  by  three  different  models: Activation, amplification, or surveillance 
(Figure 1). Each model states that RIG-I is present in the cytoplasm in resting cells, but engagement to 
a specific PAMP ligand leads to its signaling activation.  
i.  activation model. Though RIG-I is present in the cell at a low level, it is not known to signal in the 
absence  of  RNA  ligand.  The  activation  model  is  based  on  the  hypothesis  that  RIG-I  is  held  in  a 
signaling-off  conformation  through  intramolecular  interactions  of  its repressor domain and CARDs. 
However, during virus infection, RIG-I repressor domain binding to high-affinity RNA ligand, such as 
5’ppp/poly-uridine-containing RNA, leads to its release of the CARDs and placement of RIG-I in a Viruses 2011, 3                         
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signaling-on, activated state. Activated RIG-I is then competent to bind to IPS-1, leading to recruitment 
and  activation  of  signaling  proteins  within  an  IPS-1  ―signalosome‖  that  drives  the  innate  immune 
antiviral response.  
ii. amplification model. While the RLRs serve as primary drivers of innate immune signaling, they have 
also been shown to play an important role in amplifying innate immune signaling through recognition of 
RNA metabolites that are produced during virus infection by the RNAse-L endoribonuclease. RNAse-L 
is activated during virus infection through the actions of the 2’,5’-oligoadenylate synthetase (OAS) 
[24]. Cleavage of self RNA substrates by RNAse-L, such as ribosomal RNA, produces a set of small 
RNA products that can serve as RIG-I and MDA5 ligands. The binding of RIG-I or MDA5 to these 
RNA  products  and  the  resulting  innate  immune  signaling  occurs  later  during virus infection and is 
supported by the increased levels of the RLRs that are produced as a result of IFN signaling [25,26]. 
This  late-stage  RLR  signaling  through  engagement  of  RNase-L  cleavage  products  would  thereby 
mediate a critical amplification step of RLR signaling to extend and possibly diversify the innate antiviral 
state, thus serving to restrict cell-to-cell virus spread. 
iii. surveillance model. Recent work by Myong et al., 2009, suggests that a single RIG-I molecule or 
molecular unit can repeatedly move across an RNA molecule without dissociating [27]. This movement 
is achieved by activation of the DExH box RNA helicase/ATPase domain and ATP hydrolysis to induce 
translocation  of  RIG-I  along  the  RNA  molecule.  Once  RIG-I  encounters  a  PAMP  motif  (such  as 
dsRNA with 5’ppp), RIG-I stalls on the RNA and undergoes the requisite conformation change to 
trigger  signaling  activation  wherein  it  is  competent  to  bind  to  IPS-1  and  drive  the  innate  immune 
response. This model hypothesizes that RIG-I is constantly surveying the cytosol to engage self and 
non-self RNA molecules alike. By translocating along a given RNA molecule, RIG-I surveys for PAMP 
motifs that when encountered, lead to RIG-I signaling activation. Thus, RIG-I may be continuously 
working to identify non-self RNA through this surveillance feature. In addition to triggering RLR-based 
signaling  cascades,  this  binding  and  translocation  of  RIG-I  along  an  RNA  molecule  could  have 
additional antiviral benefits by inhibiting RNA-protein binding events that are critical to the viral life 
cycle, thereby directly blocking virus replication. The surveillance model also presents the possibility 
that RIG-I could aberrantly identify a self-RNA as a ligand. Such an event could aberrantly trigger 
signaling against self and potentially lead to consequences of autoimmunity or immune toxicity through 
abnormal innate immune signaling. 
4. Targeted Therapeutic Applications for RLR Agonists 
The  functional  triggering  of  innate  immune  responses,  interferon  production  and  signaling,  and 
ultimately  interferon-stimulated  gene  (ISG)  induction  by  RLRs  serve  to  initiate  the  host  immune 
response to viral infection and provide an important adjuvant action to modulate adaptive immunity 
through the actions of ISG products. A number of the host factors in antiviral defense and immune 
response pathways are ISGs that are either not expressed in resting cells or are expressed basally at low 
levels to provide surveillance against viral infection. These factors are then amplified significantly in 
response to IFN. For example, in the case of hepatitis C virus (HCV) infection, IFN signaling has been 
shown to induce an amplification loop in the innate immune response that further increases immune Viruses 2011, 3                         
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activation [28,29]. In addition to the immediate innate immune response, IFN-/ signaling also effects 
longer term immune responses by driving the maturation of dendritic cells and other antigen presenting 
cells,  and  supporting  the  differentiation  of  specific  immune  effector  cells  as  well  as  inducing  the 
production of localized proinflammatory cytokines. These parameters together serve to control cell-
mediated  defenses  and  to  modulate  the  adaptive  immune  response  to  virus  infection  [30].  Indeed, 
studies of gene profiling of liver from HCV-infected chimpanzees have indicated an association between 
a high level of ISG expression in hepatocytes and the resolution of acute HCV infection [31]. These 
studies  suggest  that  therapy  targeting  the  activation  of  innate  immune  defenses  could  limit  HCV 
infection to a level that could be controlled by the host immune defenses. While IFN currently serves as 
the standard of care therapy for HCV infection, the toxic side effects caused by its pleiotropic actions, 
in part, render it nonspecific and of low overall efficacy. Thus, the development of therapies that trigger 
specific innate immune programs and lead to select effector gene expression and function could have a 
revolutionary impact on the control of virus infection and antiviral immune enhancement against both 
chronic and acute viral infections.  
Recent  studies  have  indicated  that  RLR  agonists  in  particular  may  have  significant  therapeutic 
potential  in  limiting  viral  infection.  In  an  in  vitro  model  of  HCV  infection,  one  study  found  that 
triggering RIG-I signaling via HCV PAMP RNA treatment of cells was able to inhibit HCV infection 
[17]. Similarly, pandemic H1N1 influenza virus infection was limited in an in vitro system that activated 
RIG-I pathways by pre-exposing cells to synthetic 5’-triphosphate RNA [32]. Furthermore, preliminary 
work using either short dsRNA, short 3’ overhang 5’ppp RNA to trigger RIG-I or long dsRNA to 
trigger  MDA5  has  demonstrated  that  in  vitro  exposure  to  these  ligands  induces  innate  immune 
programs  that  can  suppress  infection  by  a  variety  of  RNA  viruses  [11,13,33–35].  Development  of  
RLR-based therapeutics should rapidly advance over the next few years, now that the structure for  
each RLR ligand binding region has been solved. These structures will enable the design of structure-
based  small  molecule  ligands  that  specifically  target  and  activate  the  RLRs  [35,36].  RLR-targeted 
therapeutics  hold  much  promise  in  fighting  viral  infection  as  they  could  induce  a  specific  adjuvant 
response tailored for enhancing immunity as well as a vaccine response to specific viruses that are 
subject to RLR recognition.  
4.1. RLRs Are Intrinsic to NK and DC Function 
Several recent studies have focused on understanding the role of RLRs in antigen presenting cell 
function. Located at the crossroads between the innate and adaptive immune response, dendritic cells 
(DCs) are a key component of the transition between the immediate and long-term response to viral 
infection. Since DCs have the unique ability to migrate through the peripherial tissues, blood stream, 
and lymphoid tissues, their ability to detect virus and alert both innate and adaptive components of the 
immune  system  by  processing  and  presenting  viral  antigens  is  central  to  inducing  robust  host  
immunity [37]. The role of PRRs in DC biology is being defined, albeit with some conflicting findings. 
DC maturation and antigen presentation ability is influenced by exposure to IFN-/ and contributes to 
directing the differentiation of CD4 T cells toward the Th1 phenotype [38]. Although PRRs are known 
to  act  as  the  second  or  third  signals  required  by  DCs  to  activate  the  differentiation  of  naïve  T 
lymphocytes to effector lymphocytes, the precise PRRs required for this response are not defined and Viruses 2011, 3                         
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are perhaps cell type and context dependent. Indeed, studies have found that in murine systems, the 
dependency of DC on RIG-I for inducing antiviral responses varies by the different DC subtypes, with 
conventional DCs relying on RLR activation and plasmocytoid DCs possibly operating independently of 
RLRs  [15,39].  In  contrast,  an  in  vitro  study  using  human  monocyte-derived  DCs  found  that 
overexpression of a dominant negative RIG-I construct completely abrogated the induction of cytokines 
induced by a recombinant Sendai virus vector and only partially inhibited expression of DC maturation 
markers CD86 and HLA-DR [40]. Recent work has shown that RLRs are differentially expressed in 
specific DC subsets, wherein CD4+ and CD4−/CD8− DCs, the RLRs may function to program antigen 
presentation and cytokine production [41]. Thus, future work needs to focus on defining the precise 
role of RLRs in the various DC populations. 
Other studies have indirectly implicated RLR signaling in DC mucosal homing, but these studies have 
not been able to differentiate between RLR and TLR signaling. Two studies have indicated that either 
TLR  or  RIG-I  signaling  in  DCs  promotes  the  mucosal  homing  of  activated  lymphocytes  [42,43]. 
Likewise,  a  zinc-finger  ubiquitin-modifying  enzyme  that  inhibits  TNF,  RIG-I,  and  TLR  signaling 
pathways, A20, was found to regulate the production of retinoic acid and proinflammatory cytokines by 
DCs.  Moreover,  this  study  found  that  A20-deficent  DCs  had  an  enhanced  ability  to  home  to  the 
draining  and  gut-associated  lymphoid  tissues  after  systematic  administration  in  mice  [44].  Thus, 
regulation of innate immune signaling may impose control of immune cell homing through modulation 
of cytokine production by inflammatory DCs. Obviously, additional work will be needed to assess the 
relative contribution, if any, of RLRs in the regulation of immune cell and DC homing. 
RLRs have also been implicated in enhancing the  function of natural killer (NK) cells. NK cells 
function  to  kill  virus-infected  target  cells  and  tumor  cells,  while  also  producing  proinflammatory 
cytokines such as TNF and IFN- that enhance innate immunity in part by inducing DC maturation. The 
mature/activated DCs then provide a positive feedback loop with the NK cells by secreting cytokines 
that enhance NK cell proliferation and cytotoxic potential. RLR receptor signaling has been implicated 
in enhancing NK/DC cross talk, as optimal IFN- production by NK cells requires the cotriggering of 
RLRs and Toll-like receptor 3 in mDCs and activation of RLRs within NK cells themselves. Indeed, 
these findings of RLR signaling in NK/DC crosstalk have immediate implications on overall immune 
responses, as recent studies have found that this cross-talk is critical for support of Th1 differentiation 
of CD4+ T cells and programming of CTL responses [45–47]. Therefore, RLRs may play an important 
role in enhancing NK cell function. 
4.2. RLRs and Inflammatory Bowel Disease  
RLRs must maintain the ability to differentiate between self and non-self RNA ligand. As mentioned 
above, the activation of RLR signaling cascades in response to self-RNA ligand interactions could have 
severely  detrimental  effects  by  inducing  an  undesired  inflammatory  reaction,  possibly  leading  to  an 
autoimmune response. In this context, recent work has implicated RLRs in driving the expansion and 
regulation of regulatory T cells [48]. In light of this finding, RLRs have been implicated as possible 
mediators of autoimmune diseases and have been associated with inflammatory bowel disease (IBD). 
IBD is a multifactorial disease characterized by a pathological inflammatory immune response in the 
intestinal mucosa, including the malfunction of T cells and aberrant cytokine production. Two recent Viruses 2011, 3                         
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studies have further implicated RIG-I in inflammatory bowel diseases, including Crohn’s disease and 
ulcerative colitis. One study found that 70% of mice lacking RIG-I gene expression developed a colitis-
like phenotype that correlates with inflammatory infiltration and severe damage in the mucosa of the 
colon [49,50]. The RIG-I-deficient mice had decreases in the size and number of Peyer’s patches, with 
an increased number of apoptotic B220+ cells within the patches. Moreover, the RIG-I −/− mice had a 
decreased number of naïve T cells, with an increased number of effector and memory CD4+ and CD8+ 
T cells in the splenic compartment, a finding which might be related to the suppression of Gi2 in these 
mice.  The  colitis-like  phenotype  of  the  RIG-I  targeted  knockout  mouse  generated  by  Wang  and 
colleagues was based on the abrogation of RIG-I expression by disrupting exons 4 to 8 of the Rig-I 
gene [49]. This phenotype directly contrasts with the embryonic lethality of another targeted RIG-I 
deficient mouse line that was generated by disrupting exons 8 to 10 [39]. The different phenotypes in 
these mouse lines could be attributed to the potential low expression levels of RIG-I truncation proteins 
generated by the targeted disruption of the RIG-I gene at different structural locations (the RIG-I −/− 
mouse displaying the colitis phenotype could possibly express truncated RIG-I with one of the 2 CARD 
domains, while the embryonic lethal RIG-I −/− knockout mouse would only express a truncated domain 
containing both CARDs). Despite these different model systems, the colitis phenotype observed in the 
report by Wang et al., 2007 suggests that RIG-I plays an important role in T cell homeostasis in the gut 
that is important for maintaining the proper balance between inflammatory activation and tolerogenicity.  
In  a  second  study  that  has  substantively  showed  the  involvement  of  RLRs  with  IBD,  the 
investigators  used  an  immunohistochemistry  approach  to  assess  RIG-I  levels  in  laser-captured 
microdissected tissues and identified a decrease in RIG-I levels in the intestinal epithelium of Crohn’s 
Disease patients [51]. Interestingly, this study found no difference in RLR expression in tissue from 
ulcerative colitis patients. These results were confirmed by RT-PCR and immunoblot analyses. While 
the pathogenesis of IBD remains to be understood, the mouse and human-based studies have indicated 
that abrogation or disregulation of RLR signaling may play a large part in the etiology of IBD. Future 
studies  will  need  to  address  the  specific  contribution  of  RLRs  to  IBD  pathogenesis  in  order  to 
determine if RLR-targeted therapeutics would have clinical application for IBD patients. 
4.3. RLRs and Immunotherapy 
Therapies that trigger the innate immune response could enhance the communication between the 
innate and adaptive immune programs, and therefore could have potential as immune adjuvants that 
enhance immune response function and long term immunity against viruses and other disease-causing 
agents. In this light, agonists that trigger RLRs or downstream signaling nodes have the potential to be 
developed as the next generation of vaccine adjuvants. Indeed, the N-CARD domain of the downstream 
RLR activator, IPS-1, has demonstrated adjuvant activity by improving humoral and cellular responses 
to  protein  vaccines  [52].  Another  study  found  that  the  establishment  of  CD8  T  cell  memory  after 
vaccination with a poly(I:C) adjuvant requires MDA5 activation [53]. Finally, the most recent study has 
directly  assessed  the  ability  of  a  RIG-I  agonist  to  function  as  an adjuvant by generating an H5N1 
influenza  virus  DNA  vaccine  vector  that  co-expressed  a  RIG-I  agonist.  Mice  given  intramuscular 
injections with these naked DNA vaccines demonstrated increased HA-specific serum antibody binding 
avidity [54]. However, the effects of this vector system on cellular immunity were limited, with CD8 Viruses 2011, 3                         
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cell epitopes only producing a less than 2-fold induction of IL-2, which is the cytokine responsible for 
increasing the number of mature CD8 T cells and enhancing CD8 immune cell memory. Additional 
work is needed to determine if the high dose of immunogen or tissue specific effects could explain the 
lack of significant induction of CD8 and CD4 cellular immune response to HIVgag in this system. 
Regardless, these studies demonstrating the ability of a RIG-I agonist containing influenza vaccine to 
stimulate  IL-2  and  improve  binding  HA-antibody  avidity  indicates  that  RLRs  are  indeed  promising 
targets for adjuvant developments. 
On a cautionary note, any unbridled activation inflammatory pathways that go unchecked can lead to 
cytokine storms that are fatal to the host. Thus, perturbations of the RLR pathways that go unmediated 
could have severe implications in maintaining the ability to mediate a healthy immune response. In this 
light, any therapeutic intervention in the RLR pathway must be carefully monitored to ensure that the 
responses induced can be adequately controlled. 
Moreover, many viruses have mechanisms to evade the innate immune response, particularly the 
RIG-I pathway. These viral evasion mechanisms have been described in detail elsewhere [55–59], but 
generally  block  RLR  signaling  by  preventing  RLR  recognition  of  viral  RNA  or  disrupting  the 
downstream signaling components. It is important to note that the evasion mechanisms used by viruses 
can allow infection to proceed despite triggering an overall antiviral immune response. Thus, RLR-
based  therapeutic  design  must  take  into  account  these  specific  viral  evasion  strategies  in  order  to 
provide the greatest clinical benefit. 
In  summary,  RLR  function  is  essential  for  host  control  of  virus  infection  by  activating  antiviral 
mechanisms of innate immunity and enhancing the adaptive immune response. Harnessing the capacity 
of RLRs to initiate powerful antiviral responses by RLR-targeted therapies has the potential to radically 
transform antiviral approaches as well as potentially serve as the basis for the next generation of vaccine 
adjuvants.  Future  studies  that  focus  on  understanding  the  role  of  RLRs  in  DC  biology  as  well  as 
proinflammatory diseases and cancer will enhance our ability to fully utilize the therapeutic potential of 
RLR agonists. 
Table 1. RIG-I-like receptors (RLRs) Ligands. 
  RIG-I  MDA5 
Viral Nucleic Acid Structure 
5’-ppp RNA + poly-uridine 
RNAase-L products 
Long ds RNA 
RNA replication intermediates 
RNAse-L products 
Synthetic Ligands  In vitro transcribed RNA, see [60]  poly(I:C) 
Virus 
Reovirus 
Dengue virus 
West Nile virus 
Rotavirus 
Sendai virus 
Vesicular stomatitis virus 
Respiratory syncytial virus 
Influenza A virus 
Ebola virus 
Hepatitis C virus 
Japanese encephalitis virus 
Newcastle disease virus 
RNA pol III transcription products 
Reovirus 
Dengue virus 
West Nile virus 
Rotavirus 
Sendai virus 
Polio virus 
Encephalomyocarditis 
Mengo virus 
Theiler’s virus 
murine norovirus Viruses 2011, 3                         
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Figure  1.  Potential  models  of  RIG-I-like  receptors  (RLRs)  surveillance  and  activation.  
(A) Activation model. RIG-I is held in a signaling-off conformation through intramolecular 
interactions  between  the  repressor  and  CARD  domains.  During  virus  infection,  RIG-I 
repressor domain binding to high-affinity RNA ligand PAMP motifs (red box) leads to RIG-
I activation and the release of the CARD domains for interaction with IPS-1 localized on 
intracellular  membranes,  ultimately  activating  signaling  proteins  within  an  IPS-1 
―signalosome‖ that drives the innate immune antiviral response. (B) Amplification model. 
During virus infection, OAS is activated, producing 2-5 A, which in turn, activates RNAse-
L cleavage of self and/or viral RNA substrates (delineated in blue), and generating products 
that then serve as RIG-I and MDA5 ligands. Binding of RIG-I or MDA5 to the RNAse-L-
generated RNA products occurs later during virus infection and is supported by increased 
RLR levels produced as a result of IFN signaling, thus creating an amplification of RLR 
signaling. (C) Surveillance model. Powered by ATP hydrolysis, a single RIG-I molecule or 
molecular unit repeatedly moves across an RNA molecule, but without dissociating. Once 
the RIG-I molecule encounters a PAMP motif, it stalls on the RNA, and ATP hydrolysis 
drives a conformation change to trigger RIG-I signaling activation, thus allowing it to bind 
to IPS-1 and induce the innate immune response.  
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